论文部分内容阅读
本研究评估CD58在急性B淋巴细胞白血病(B-ALL)近期疗效判断中的价值。应用四色流式细胞分析技术观察135例儿童期B-ALL患者CD58分子的表达特点;建立用CD58/CD10/CD34/CD19抗体组合检测B-ALLMRD的方案;结合CD58的表达情况和MRD监测结果分析CD58在B-ALL中的预后价值。结果表明135例B-ALL的平均CD58MFI为113.08±63.33,15例正常骨髓的CD19+CD10+细胞的平均CD58MFI为14.68±5.26,两者差异显著(P<0.01);51.9%(70/135)B-ALL患者的CD58分子强表达,可以用CD58为指标进行MRD检测;CD58/CD10/CD34/CD19抗体组合的有效频率仅次于TdT/CD10/CD34/CD19,为51.9%;CD58高表达组的MRD阳性率显著低于CD58低表达组(P<0.05)。结论CD58可以作为B-ALLMRD检测的指标,此结果丰富了MRD检测的组合;CD58的高表达可以作为B-ALL预后较好的指标。
This study evaluated the value of CD58 in judging the short-term efficacy of acute lymphoblastic leukemia (B-ALL). The expression characteristics of CD58 in 135 cases of childhood B-ALL patients were observed by using four-color flow cytometry. The protocol of detecting B-ALLMRD by CD58 / CD10 / CD34 / CD19 antibody combination was established. Combined with the expression of CD58 and MRD results The prognostic value of CD58 in B-ALL was analyzed. The mean CD58MFI of 135 B-ALL patients was 113.08 ± 63.33. The mean CD58MFI of CD19 + CD10 + cells in 15 normal bone marrow samples was 14.68 ± 5.26 (51.9%, 70/135) -ALL patients with strong expression of CD58 molecules, CD58 can be used as an indicator of MRD detection; CD58 / CD10 / CD34 / CD19 antibody combination frequency of effective second only to TdT / CD10 / CD34 / CD19, 51.9%; CD58 high expression group The positive rate of MRD was significantly lower than that of CD58 low expression group (P <0.05). Conclusion CD58 can be used as a marker for B-ALLMRD detection. This result enriches the combination of MRD detection. High expression of CD58 can be used as a good indicator of B-ALL prognosis.